XSAT:EQL (Sweden)
Business Description
EQL Pharma AB
Stortorget 1, 3rd Floor, Lund, SWE, 222 23
Compare
Compare
Traded in other countries / regions
7JK.Germany
•
EQL.Sweden
Description
EQL Pharma AB is a pharmaceutical company engaged in developing and selling medicines to pharmacies and hospitals. The products offered by the company include generics and parallel imports. It operates and markets products to Nordic countries of Sweden, Denmark, Finland and Norway.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.54 | |||||
| Equity-to-Asset | 0.52 | |||||
| Debt-to-Equity | 0.62 | |||||
| Debt-to-EBITDA | 1.96 | |||||
| Interest Coverage | 13.42 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 7.52 | |||||
| Beneish M-Score | -1.64 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 101.9 | |||||
| 3-Year EBITDA Growth Rate | 125.8 | |||||
| 3-Year Book Growth Rate | 16.5 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.28 | |||||
| 9-Day RSI | 44.62 | |||||
| 14-Day RSI | 48.4 | |||||
| 6-1 Month Momentum % | -22.13 | |||||
| 12-1 Month Momentum % | -23.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.25 | |||||
| Quick Ratio | 0.83 | |||||
| Cash Ratio | 0.42 | |||||
| Days Inventory | 76.33 | |||||
| Days Sales Outstanding | 40.72 | |||||
| Days Payable | 31.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 23.48 | |||||
| Operating Margin % | 9.4 | |||||
| Net Margin % | 7.69 | |||||
| ROE % | 30.04 | |||||
| ROA % | 12.49 | |||||
| ROIC % | 15.38 | |||||
| ROC (Joel Greenblatt) % | 51.9 | |||||
| ROCE % | 32.59 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 27.42 | |||||
| PE Ratio without NRI | 28.79 | |||||
| Shiller PE Ratio | 4865.7 | |||||
| PEG Ratio | 0.47 | |||||
| PS Ratio | 2.12 | |||||
| PB Ratio | 7.05 | |||||
| Price-to-Tangible-Book | 65.22 | |||||
| Price-to-Free-Cash-Flow | 44.25 | |||||
| Price-to-Operating-Cash-Flow | 20.87 | |||||
| EV-to-EBIT | 23.34 | |||||
| EV-to-EBITDA | 23.34 | |||||
| EV-to-Revenue | 2.21 | |||||
| EV-to-FCF | 48.15 | |||||
| Price-to-Projected-FCF | 5.64 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.1 | |||||
| Price-to-Graham-Number | 8.93 | |||||
| Price-to-Net-Current-Asset-Value | 93.75 | |||||
| Earnings Yield (Greenblatt) % | 4.29 | |||||
| Forward Rate of Return (Yacktman) % | 20.48 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 410.386 | ||
| EPS (TTM) (kr) | 1.094 | ||
| Beta | 0.78 | ||
| Volatility % | 33.22 | ||
| 14-Day RSI | 48.4 | ||
| 14-Day ATR (kr) | 1.979782 | ||
| 20-Day SMA (kr) | 30.395 | ||
| 12-1 Month Momentum % | -23.63 | ||
| 52-Week Range (kr) | 24.9 - 48.7 | ||
| Shares Outstanding (Mil) | 29.06 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
EQL Pharma AB Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||